NBIX Neurocrine Biosciences Inc

Price (delayed)

$98.52

Market cap

$9.31B

P/E Ratio

22.81

Dividend/share

N/A

EPS

$4.32

Enterprise value

$9.39B

Neurocrine Biosciences is a publicly traded biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological ...

Highlights
The company's net income has surged by 128% YoY
NBIX's EPS has surged by 125% year-on-year
Neurocrine Biosciences's quick ratio has decreased by 18% YoY but it has increased by 4.7% from the previous quarter
The debt is down by 14% YoY but it is up by 4.2% QoQ

Key stats

What are the main financial stats of NBIX
Market
Shares outstanding
94.55M
Market cap
$9.31B
Enterprise value
$9.39B
Valuations
Price to earnings (P/E)
22.81
Price to book (P/B)
7.68
Price to sales (P/S)
8.88
EV/EBIT
74.51
EV/EBITDA
69.54
EV/Sales
8.98
Earnings
Revenue
$1.05B
EBIT
$126M
EBITDA
$135M
Free cash flow
$263.5M
Per share
EPS
$4.32
Free cash flow per share
$2.8
Book value per share
$12.83
Revenue per share
$11.1
TBVPS
$19.6
Balance sheet
Total assets
$1.85B
Total liabilities
$640.8M
Debt
$429.5M
Equity
$1.21B
Working capital
$895.4M
Liquidity
Debt to equity
0.36
Current ratio
5.71
Quick ratio
5.39
Net debt/EBITDA
0.55
Margins
EBITDA margin
12.9%
Gross margin
99%
Net margin
38.5%
Operating margin
13%
Efficiency
Return on assets
24.4%
Return on equity
40.5%
Return on invested capital
9.2%
Return on capital employed
7.6%
Return on sales
12.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NBIX stock price

How has the Neurocrine Biosciences stock price performed over time
Intraday
0.4%
1 week
3.72%
1 month
-1.74%
1 year
-23.12%
YTD
2.79%
QTD
1.23%

Financial performance

How have Neurocrine Biosciences's revenue and profit performed over time
Revenue
$1.05B
Gross profit
$1.03B
Operating income
$135.6M
Net income
$402M
Gross margin
99%
Net margin
38.5%
The company's net income has surged by 128% YoY
The net margin has soared by 93% YoY
The operating margin has plunged by 50% YoY and by 17% from the previous quarter
The operating income has declined by 42% year-on-year and by 17% since the previous quarter

Growth

What is Neurocrine Biosciences's growth rate over time

Valuation

What is Neurocrine Biosciences stock price valuation
P/E
22.81
P/B
7.68
P/S
8.88
EV/EBIT
74.51
EV/EBITDA
69.54
EV/Sales
8.98
NBIX's EPS has surged by 125% year-on-year
The price to earnings (P/E) is 53% lower than the last 4 quarters average of 48.6
The company's equity has surged by 72% YoY and by 7% QoQ
NBIX's price to book (P/B) is 48% lower than its 5-year quarterly average of 14.9 and 24% lower than its last 4 quarters average of 10.1
The stock's price to sales (P/S) is 89% less than its 5-year quarterly average of 82.2 and 4.5% less than its last 4 quarters average of 9.3
Neurocrine Biosciences's revenue has increased by 18% YoY

Efficiency

How efficient is Neurocrine Biosciences business performance
Neurocrine Biosciences's return on assets has surged by 69% YoY but it has decreased by 8% QoQ
NBIX's return on sales has dropped by 51% year-on-year and by 9% since the previous quarter
The company's return on invested capital fell by 45% YoY and by 12% QoQ
The ROE has grown by 37% YoY but it has contracted by 14% from the previous quarter

Dividends

What is NBIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NBIX.

Financial health

How did Neurocrine Biosciences financials performed over time
NBIX's total assets is 188% more than its total liabilities
NBIX's total assets is up by 36% YoY and by 6% from the previous quarter
Neurocrine Biosciences's quick ratio has decreased by 18% YoY but it has increased by 4.7% from the previous quarter
The debt is 64% lower than the equity
The company's equity has surged by 72% YoY and by 7% QoQ
NBIX's debt to equity is down by 49% year-on-year and by 2.7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.